# GXR RM China BE Study (Darmstadt - Jiangsu)

> **NCT05463094** · PHASE1 · COMPLETED · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 84 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Test Glucophage® XR
- **DRUG:** Reference Glucophage® XR

## Key facts

- **NCT ID:** NCT05463094
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-25
- **Primary completion:** 2023-01-03
- **Final completion:** 2023-01-03
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2023-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05463094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05463094, "GXR RM China BE Study (Darmstadt - Jiangsu)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05463094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*